Experimental drug in human trials enables tooth regeneration

A groundbreaking experimental therapy in Japan is now in human trials, targeting the protein USAG-1—a key suppressor of tooth development. The drug works by blocking USAG-1, allowing dormant tooth buds to regrow a functional tooth. The first human trial, focusing on children with congenital tooth agenesis, began in earnest this year, building on promising preclinical results. Scientists aim for wider public availability by 2030. This innovation represents a major leap toward regenerating natural teeth without implants or prosthetics, potentially revolutionizing dental care and offering hope for those who lack conventional dental replacement options